Burford Capital Limited General and Administrative Expenses 2011-2026 | BUR

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Burford Capital Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	99.3 M	9.6 M	415 K	348 K	315 K	348 K	381 K	359 K	335 K	8.64 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
99.3 M	315 K	12 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Black Diamond Therapeutics BDTX	27.5 M	$ 2.38	-3.64 %	$ 131 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	54 M	$ 2.1	-13.79 %	$ 216 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	13.9 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Athira Pharma ATHA	26.1 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	21 M	$ 4.2	-2.67 %	$ 298 M	USA
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Athersys ATHX	20.1 M	-	3.77 %	$ 22.4 M	USA
Axcella Health AXLA	15.8 M	-	-16.42 %	$ 249 M	USA
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
AVEO Pharmaceuticals AVEO	60.8 M	-	-	$ 521 M	USA
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Apellis Pharmaceuticals APLS	550 M	$ 20.61	-1.67 %	$ 2.6 B	USA
Agenus AGEN	78.7 M	$ 3.33	-	$ 1.19 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Agios Pharmaceuticals AGIO	180 M	$ 28.87	-4.5 %	$ 1.67 B	USA
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA